Brief: Nanjing Leads Biolabs Says FDA Grants Fast Track Designation To LBL-024
11/10/2026 23:52
BRIEF-Nanjing Leads Biolabs Says FDA Grants Fast Track Designation To LBL-024 Oct 12 (Reuters) - Nanjing Leads Biolabs Co Ltd 9887.HK:
FDA GRANTS FAST TRACK DESIGNATION TO LBL-024 FOR FIRST-LINE ADVANCED BILIARY TRACT CANCER
Further company coverage: 9887.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanjing Leads Biolabs
See all newsBrief: Nanjing Leads Biolabs Says FDA Grants Fast Track Designation To LBL-024
Brief: Nanjing Leads Biolabs Posts HY Loss Attributable RMB221.9 Million
Nanjing Leads rises on clinical study progress on cancer treatment drug
Nanjing Leads Biolabs jumps on progress of tumor antibody treatment
Nanjing Leads Biolabs rises on NMPA's IND approval for colorectal cancer